nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0592	0.126	CbGbCtD
Lurasidone—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0557	0.119	CbGbCtD
Lurasidone—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0557	0.119	CbGbCtD
Lurasidone—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0504	0.107	CbGbCtD
Lurasidone—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0504	0.107	CbGbCtD
Lurasidone—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0435	0.0925	CbGbCtD
Lurasidone—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0422	0.0898	CbGbCtD
Lurasidone—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0382	0.0812	CbGbCtD
Lurasidone—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0382	0.0812	CbGbCtD
Lurasidone—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0366	0.0779	CbGbCtD
Lurasidone—HTR7—nerve—acquired immunodeficiency syndrome	0.00459	0.0631	CbGeAlD
Lurasidone—DRD2—nerve—acquired immunodeficiency syndrome	0.00434	0.0597	CbGeAlD
Lurasidone—HTR7—endothelium—acquired immunodeficiency syndrome	0.00391	0.0537	CbGeAlD
Lurasidone—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.00363	0.0499	CbGeAlD
Lurasidone—HTR7—blood plasma—acquired immunodeficiency syndrome	0.00347	0.0477	CbGeAlD
Lurasidone—HTR2A—nerve—acquired immunodeficiency syndrome	0.00286	0.0394	CbGeAlD
Lurasidone—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.00255	0.035	CbGeAlD
Lurasidone—HTR2A—endothelium—acquired immunodeficiency syndrome	0.00244	0.0335	CbGeAlD
Lurasidone—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.00217	0.0298	CbGeAlD
Lurasidone—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.002	0.0276	CbGeAlD
Lurasidone—DRD2—retina—acquired immunodeficiency syndrome	0.0018	0.0247	CbGeAlD
Lurasidone—HTR7—digestive system—acquired immunodeficiency syndrome	0.00134	0.0184	CbGeAlD
Lurasidone—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.00128	0.0176	CbGeAlD
Lurasidone—HTR7—blood—acquired immunodeficiency syndrome	0.00127	0.0175	CbGeAlD
Lurasidone—HTR7—spinal cord—acquired immunodeficiency syndrome	0.00123	0.0168	CbGeAlD
Lurasidone—HTR2A—retina—acquired immunodeficiency syndrome	0.00119	0.0163	CbGeAlD
Lurasidone—ADRA2C—blood—acquired immunodeficiency syndrome	0.00117	0.0161	CbGeAlD
Lurasidone—ADRA2C—spinal cord—acquired immunodeficiency syndrome	0.00113	0.0155	CbGeAlD
Lurasidone—HTR7—lung—acquired immunodeficiency syndrome	0.00112	0.0153	CbGeAlD
Lurasidone—ADRA2C—vagina—acquired immunodeficiency syndrome	0.00108	0.0149	CbGeAlD
Lurasidone—HTR1A—nervous system—acquired immunodeficiency syndrome	0.00108	0.0149	CbGeAlD
Lurasidone—DRD2—lung—acquired immunodeficiency syndrome	0.00105	0.0145	CbGeAlD
Lurasidone—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.00104	0.0143	CbGeAlD
Lurasidone—HTR7—nervous system—acquired immunodeficiency syndrome	0.00103	0.0142	CbGeAlD
Lurasidone—ADRA2C—lung—acquired immunodeficiency syndrome	0.00103	0.0141	CbGeAlD
Lurasidone—HTR7—central nervous system—acquired immunodeficiency syndrome	0.000994	0.0137	CbGeAlD
Lurasidone—DRD2—nervous system—acquired immunodeficiency syndrome	0.000976	0.0134	CbGeAlD
Lurasidone—ADRA2C—nervous system—acquired immunodeficiency syndrome	0.000949	0.013	CbGeAlD
Lurasidone—DRD2—central nervous system—acquired immunodeficiency syndrome	0.00094	0.0129	CbGeAlD
Lurasidone—ADRA2A—blood—acquired immunodeficiency syndrome	0.000933	0.0128	CbGeAlD
Lurasidone—ADRA2C—central nervous system—acquired immunodeficiency syndrome	0.000914	0.0126	CbGeAlD
Lurasidone—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.000899	0.0124	CbGeAlD
Lurasidone—ADRA2A—vagina—acquired immunodeficiency syndrome	0.000865	0.0119	CbGeAlD
Lurasidone—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000833	0.0114	CbGeAlD
Lurasidone—HTR1A—brain—acquired immunodeficiency syndrome	0.000826	0.0114	CbGeAlD
Lurasidone—ADRA2A—lung—acquired immunodeficiency syndrome	0.000818	0.0112	CbGeAlD
Lurasidone—HTR2A—blood—acquired immunodeficiency syndrome	0.000793	0.0109	CbGeAlD
Lurasidone—HTR7—brain—acquired immunodeficiency syndrome	0.000789	0.0109	CbGeAlD
Lurasidone—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000771	0.0106	CbGeAlD
Lurasidone—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000764	0.0105	CbGeAlD
Lurasidone—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.000757	0.0104	CbGeAlD
Lurasidone—DRD2—brain—acquired immunodeficiency syndrome	0.000746	0.0103	CbGeAlD
Lurasidone—HTR2A—vagina—acquired immunodeficiency syndrome	0.000735	0.0101	CbGeAlD
Lurasidone—CYP3A4—blood—acquired immunodeficiency syndrome	0.000734	0.0101	CbGeAlD
Lurasidone—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.000729	0.01	CbGeAlD
Lurasidone—ADRA2C—brain—acquired immunodeficiency syndrome	0.000726	0.00997	CbGeAlD
Lurasidone—ADRA2C—lymph node—acquired immunodeficiency syndrome	0.000701	0.00964	CbGeAlD
Lurasidone—HTR2A—lung—acquired immunodeficiency syndrome	0.000695	0.00956	CbGeAlD
Lurasidone—HTR2A—nervous system—acquired immunodeficiency syndrome	0.000644	0.00885	CbGeAlD
Lurasidone—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.00062	0.00852	CbGeAlD
Lurasidone—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000596	0.0082	CbGeAlD
Lurasidone—ADRA2A—brain—acquired immunodeficiency syndrome	0.000579	0.00796	CbGeAlD
Lurasidone—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000574	0.00789	CbGeAlD
Lurasidone—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.000559	0.00769	CbGeAlD
Lurasidone—HTR2A—brain—acquired immunodeficiency syndrome	0.000492	0.00677	CbGeAlD
Lurasidone—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000396	0.000934	CcSEcCtD
Lurasidone—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000395	0.000931	CcSEcCtD
Lurasidone—Loss of consciousness—Delavirdine—acquired immunodeficiency syndrome	0.000394	0.000929	CcSEcCtD
Lurasidone—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.000394	0.000928	CcSEcCtD
Lurasidone—Flatulence—Saquinavir—acquired immunodeficiency syndrome	0.000393	0.000927	CcSEcCtD
Lurasidone—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000393	0.000927	CcSEcCtD
Lurasidone—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.000392	0.000923	CcSEcCtD
Lurasidone—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.000391	0.000921	CcSEcCtD
Lurasidone—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.00039	0.00092	CcSEcCtD
Lurasidone—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.00039	0.00092	CcSEcCtD
Lurasidone—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.000389	0.000916	CcSEcCtD
Lurasidone—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000388	0.000915	CcSEcCtD
Lurasidone—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000387	0.000913	CcSEcCtD
Lurasidone—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.000387	0.000912	CcSEcCtD
Lurasidone—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000386	0.00091	CcSEcCtD
Lurasidone—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.000384	0.000905	CcSEcCtD
Lurasidone—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.000383	0.000904	CcSEcCtD
Lurasidone—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000383	0.000904	CcSEcCtD
Lurasidone—Myalgia—Delavirdine—acquired immunodeficiency syndrome	0.000382	0.0009	CcSEcCtD
Lurasidone—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.000381	0.000899	CcSEcCtD
Lurasidone—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000381	0.000898	CcSEcCtD
Lurasidone—Anxiety—Delavirdine—acquired immunodeficiency syndrome	0.000381	0.000897	CcSEcCtD
Lurasidone—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000379	0.000892	CcSEcCtD
Lurasidone—Shock—Efavirenz—acquired immunodeficiency syndrome	0.000376	0.000887	CcSEcCtD
Lurasidone—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000376	0.000886	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000376	0.000886	CcSEcCtD
Lurasidone—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000375	0.000885	CcSEcCtD
Lurasidone—Flatulence—Lamivudine—acquired immunodeficiency syndrome	0.000375	0.000885	CcSEcCtD
Lurasidone—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000375	0.000884	CcSEcCtD
Lurasidone—Malaise—Ritonavir—acquired immunodeficiency syndrome	0.000374	0.000882	CcSEcCtD
Lurasidone—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000374	0.000882	CcSEcCtD
Lurasidone—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000374	0.00088	CcSEcCtD
Lurasidone—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000373	0.00088	CcSEcCtD
Lurasidone—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.000373	0.000878	CcSEcCtD
Lurasidone—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000372	0.000878	CcSEcCtD
Lurasidone—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000372	0.000877	CcSEcCtD
Lurasidone—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000372	0.000876	CcSEcCtD
Lurasidone—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	0.000371	0.000875	CcSEcCtD
Lurasidone—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.00037	0.000872	CcSEcCtD
Lurasidone—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.000369	0.00087	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000369	0.00087	CcSEcCtD
Lurasidone—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000368	0.000868	CcSEcCtD
Lurasidone—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000367	0.000865	CcSEcCtD
Lurasidone—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000367	0.000865	CcSEcCtD
Lurasidone—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000367	0.000865	CcSEcCtD
Lurasidone—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000366	0.000863	CcSEcCtD
Lurasidone—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000366	0.000863	CcSEcCtD
Lurasidone—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000365	0.000859	CcSEcCtD
Lurasidone—Rash—Didanosine—acquired immunodeficiency syndrome	0.000364	0.000858	CcSEcCtD
Lurasidone—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000364	0.000857	CcSEcCtD
Lurasidone—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000364	0.000857	CcSEcCtD
Lurasidone—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000361	0.000851	CcSEcCtD
Lurasidone—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000361	0.00085	CcSEcCtD
Lurasidone—Shock—Delavirdine—acquired immunodeficiency syndrome	0.00036	0.000849	CcSEcCtD
Lurasidone—Malaise—Saquinavir—acquired immunodeficiency syndrome	0.00036	0.000849	CcSEcCtD
Lurasidone—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.00036	0.000849	CcSEcCtD
Lurasidone—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000359	0.000847	CcSEcCtD
Lurasidone—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000359	0.000847	CcSEcCtD
Lurasidone—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000359	0.000846	CcSEcCtD
Lurasidone—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000358	0.000844	CcSEcCtD
Lurasidone—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000358	0.000844	CcSEcCtD
Lurasidone—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.000357	0.000842	CcSEcCtD
Lurasidone—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000357	0.000842	CcSEcCtD
Lurasidone—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000357	0.000841	CcSEcCtD
Lurasidone—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000357	0.00084	CcSEcCtD
Lurasidone—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000356	0.000839	CcSEcCtD
Lurasidone—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000356	0.000838	CcSEcCtD
Lurasidone—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000356	0.000838	CcSEcCtD
Lurasidone—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000355	0.000837	CcSEcCtD
Lurasidone—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000354	0.000836	CcSEcCtD
Lurasidone—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000354	0.000835	CcSEcCtD
Lurasidone—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000354	0.000834	CcSEcCtD
Lurasidone—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000353	0.000832	CcSEcCtD
Lurasidone—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000352	0.00083	CcSEcCtD
Lurasidone—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000352	0.00083	CcSEcCtD
Lurasidone—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000352	0.00083	CcSEcCtD
Lurasidone—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000351	0.000827	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000351	0.000827	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.00035	0.000824	CcSEcCtD
Lurasidone—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000349	0.000823	CcSEcCtD
Lurasidone—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000349	0.000823	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000349	0.000822	CcSEcCtD
Lurasidone—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000348	0.00082	CcSEcCtD
Lurasidone—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000346	0.000816	CcSEcCtD
Lurasidone—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000346	0.000815	CcSEcCtD
Lurasidone—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000345	0.000814	CcSEcCtD
Lurasidone—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000345	0.000813	CcSEcCtD
Lurasidone—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000344	0.000811	CcSEcCtD
Lurasidone—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000344	0.00081	CcSEcCtD
Lurasidone—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000344	0.00081	CcSEcCtD
Lurasidone—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000343	0.000808	CcSEcCtD
Lurasidone—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000343	0.000808	CcSEcCtD
Lurasidone—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000342	0.000807	CcSEcCtD
Lurasidone—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000342	0.000806	CcSEcCtD
Lurasidone—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000342	0.000805	CcSEcCtD
Lurasidone—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000341	0.000804	CcSEcCtD
Lurasidone—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000341	0.000804	CcSEcCtD
Lurasidone—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.00034	0.000802	CcSEcCtD
Lurasidone—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.00034	0.000801	CcSEcCtD
Lurasidone—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000339	0.000798	CcSEcCtD
Lurasidone—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000338	0.000796	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000338	0.000796	CcSEcCtD
Lurasidone—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000337	0.000794	CcSEcCtD
Lurasidone—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000335	0.000789	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000334	0.000786	CcSEcCtD
Lurasidone—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000333	0.000785	CcSEcCtD
Lurasidone—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000333	0.000784	CcSEcCtD
Lurasidone—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000332	0.000784	CcSEcCtD
Lurasidone—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000332	0.000783	CcSEcCtD
Lurasidone—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000332	0.000783	CcSEcCtD
Lurasidone—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000331	0.000781	CcSEcCtD
Lurasidone—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000331	0.000781	CcSEcCtD
Lurasidone—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000331	0.00078	CcSEcCtD
Lurasidone—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.00033	0.000779	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.00033	0.000779	CcSEcCtD
Lurasidone—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.00033	0.000778	CcSEcCtD
Lurasidone—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.00033	0.000778	CcSEcCtD
Lurasidone—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.00033	0.000778	CcSEcCtD
Lurasidone—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000329	0.000775	CcSEcCtD
Lurasidone—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000327	0.000771	CcSEcCtD
Lurasidone—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000327	0.000771	CcSEcCtD
Lurasidone—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000327	0.00077	CcSEcCtD
Lurasidone—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000326	0.000769	CcSEcCtD
Lurasidone—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000326	0.000769	CcSEcCtD
Lurasidone—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000325	0.000767	CcSEcCtD
Lurasidone—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000324	0.000764	CcSEcCtD
Lurasidone—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000324	0.000763	CcSEcCtD
Lurasidone—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000323	0.000762	CcSEcCtD
Lurasidone—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000322	0.00076	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000322	0.000759	CcSEcCtD
Lurasidone—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000321	0.000756	CcSEcCtD
Lurasidone—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.00032	0.000755	CcSEcCtD
Lurasidone—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.00032	0.000753	CcSEcCtD
Lurasidone—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.00032	0.000753	CcSEcCtD
Lurasidone—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000319	0.000751	CcSEcCtD
Lurasidone—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000318	0.00075	CcSEcCtD
Lurasidone—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000317	0.000748	CcSEcCtD
Lurasidone—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000317	0.000747	CcSEcCtD
Lurasidone—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000317	0.000746	CcSEcCtD
Lurasidone—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000317	0.000746	CcSEcCtD
Lurasidone—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000316	0.000746	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000316	0.000745	CcSEcCtD
Lurasidone—Rash—Stavudine—acquired immunodeficiency syndrome	0.000316	0.000745	CcSEcCtD
Lurasidone—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000316	0.000744	CcSEcCtD
Lurasidone—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000316	0.000744	CcSEcCtD
Lurasidone—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000315	0.000743	CcSEcCtD
Lurasidone—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000314	0.00074	CcSEcCtD
Lurasidone—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000313	0.000738	CcSEcCtD
Lurasidone—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000312	0.000736	CcSEcCtD
Lurasidone—Rash—Abacavir—acquired immunodeficiency syndrome	0.000311	0.000734	CcSEcCtD
Lurasidone—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000311	0.000733	CcSEcCtD
Lurasidone—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000309	0.000728	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000308	0.000727	CcSEcCtD
Lurasidone—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000308	0.000727	CcSEcCtD
Lurasidone—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000308	0.000726	CcSEcCtD
Lurasidone—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000306	0.000722	CcSEcCtD
Lurasidone—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000306	0.000721	CcSEcCtD
Lurasidone—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000305	0.000719	CcSEcCtD
Lurasidone—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000305	0.000718	CcSEcCtD
Lurasidone—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000303	0.000713	CcSEcCtD
Lurasidone—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000302	0.000712	CcSEcCtD
Lurasidone—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000302	0.000711	CcSEcCtD
Lurasidone—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000301	0.000709	CcSEcCtD
Lurasidone—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000301	0.000708	CcSEcCtD
Lurasidone—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000299	0.000706	CcSEcCtD
Lurasidone—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000299	0.000704	CcSEcCtD
Lurasidone—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000298	0.000702	CcSEcCtD
Lurasidone—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000298	0.000702	CcSEcCtD
Lurasidone—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000298	0.000701	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000297	0.0007	CcSEcCtD
Lurasidone—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000295	0.000695	CcSEcCtD
Lurasidone—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000294	0.000694	CcSEcCtD
Lurasidone—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000293	0.000691	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000292	0.000689	CcSEcCtD
Lurasidone—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000292	0.000688	CcSEcCtD
Lurasidone—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000291	0.000685	CcSEcCtD
Lurasidone—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000291	0.000685	CcSEcCtD
Lurasidone—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.00029	0.000685	CcSEcCtD
Lurasidone—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.00029	0.000683	CcSEcCtD
Lurasidone—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000289	0.000682	CcSEcCtD
Lurasidone—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000288	0.000679	CcSEcCtD
Lurasidone—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000287	0.000676	CcSEcCtD
Lurasidone—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000287	0.000675	CcSEcCtD
Lurasidone—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000283	0.000668	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000283	0.000668	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000281	0.000663	CcSEcCtD
Lurasidone—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000281	0.000663	CcSEcCtD
Lurasidone—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000281	0.000662	CcSEcCtD
Lurasidone—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000277	0.000653	CcSEcCtD
Lurasidone—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000277	0.000653	CcSEcCtD
Lurasidone—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000277	0.000653	CcSEcCtD
Lurasidone—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000277	0.000653	CcSEcCtD
Lurasidone—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000276	0.000651	CcSEcCtD
Lurasidone—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000275	0.000647	CcSEcCtD
Lurasidone—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000275	0.000647	CcSEcCtD
Lurasidone—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000274	0.000647	CcSEcCtD
Lurasidone—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000274	0.000645	CcSEcCtD
Lurasidone—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000271	0.000638	CcSEcCtD
Lurasidone—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.00027	0.000637	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000268	0.000633	CcSEcCtD
Lurasidone—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000268	0.000632	CcSEcCtD
Lurasidone—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000268	0.000631	CcSEcCtD
Lurasidone—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000268	0.000631	CcSEcCtD
Lurasidone—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000266	0.000628	CcSEcCtD
Lurasidone—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000263	0.000619	CcSEcCtD
Lurasidone—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000262	0.000617	CcSEcCtD
Lurasidone—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000259	0.000611	CcSEcCtD
Lurasidone—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000259	0.00061	CcSEcCtD
Lurasidone—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000258	0.000607	CcSEcCtD
Lurasidone—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000258	0.000607	CcSEcCtD
Lurasidone—Rash—Indinavir—acquired immunodeficiency syndrome	0.000255	0.000602	CcSEcCtD
Lurasidone—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000255	0.000601	CcSEcCtD
Lurasidone—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000254	0.000599	CcSEcCtD
Lurasidone—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000253	0.000596	CcSEcCtD
Lurasidone—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000251	0.00059	CcSEcCtD
Lurasidone—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000246	0.000579	CcSEcCtD
Lurasidone—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000243	0.000573	CcSEcCtD
Lurasidone—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000243	0.000573	CcSEcCtD
Lurasidone—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000242	0.000571	CcSEcCtD
Lurasidone—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000241	0.000569	CcSEcCtD
Lurasidone—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000241	0.000568	CcSEcCtD
Lurasidone—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000241	0.000567	CcSEcCtD
Lurasidone—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.00024	0.000565	CcSEcCtD
Lurasidone—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000234	0.000551	CcSEcCtD
Lurasidone—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000233	0.000549	CcSEcCtD
Lurasidone—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000232	0.000546	CcSEcCtD
Lurasidone—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000231	0.000544	CcSEcCtD
Lurasidone—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000231	0.000544	CcSEcCtD
Lurasidone—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000231	0.000543	CcSEcCtD
Lurasidone—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000227	0.000536	CcSEcCtD
Lurasidone—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000224	0.000528	CcSEcCtD
Lurasidone—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000223	0.000526	CcSEcCtD
Lurasidone—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000223	0.000526	CcSEcCtD
Lurasidone—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.00022	0.000518	CcSEcCtD
Lurasidone—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000217	0.000513	CcSEcCtD
Lurasidone—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000215	0.000508	CcSEcCtD
Lurasidone—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000215	0.000507	CcSEcCtD
Lurasidone—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000213	0.000503	CcSEcCtD
Lurasidone—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000213	0.000503	CcSEcCtD
Lurasidone—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000213	0.000501	CcSEcCtD
Lurasidone—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000207	0.000488	CcSEcCtD
Lurasidone—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000206	0.000485	CcSEcCtD
Lurasidone—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000205	0.000484	CcSEcCtD
Lurasidone—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000205	0.000484	CcSEcCtD
Lurasidone—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000201	0.000474	CcSEcCtD
Lurasidone—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000198	0.000466	CcSEcCtD
Lurasidone—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000196	0.000462	CcSEcCtD
Lurasidone—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000196	0.000462	CcSEcCtD
Lurasidone—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000194	0.000456	CcSEcCtD
Lurasidone—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000185	0.000435	CcSEcCtD
Lurasidone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	8.99e-05	0.00273	CbGpPWpGaD
Lurasidone—DRD2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	8.95e-05	0.00272	CbGpPWpGaD
Lurasidone—ADRA2A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	8.89e-05	0.0027	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—TAT—acquired immunodeficiency syndrome	8.85e-05	0.00269	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	8.8e-05	0.00267	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	8.71e-05	0.00265	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	8.71e-05	0.00265	CbGpPWpGaD
Lurasidone—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	8.7e-05	0.00264	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.58e-05	0.0026	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	8.51e-05	0.00258	CbGpPWpGaD
Lurasidone—DRD2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	8.41e-05	0.00255	CbGpPWpGaD
Lurasidone—HTR7—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	8.33e-05	0.00253	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	8.32e-05	0.00253	CbGpPWpGaD
Lurasidone—DRD2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	8.3e-05	0.00252	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.3e-05	0.00252	CbGpPWpGaD
Lurasidone—HTR2A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	8.27e-05	0.00251	CbGpPWpGaD
Lurasidone—HTR2A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	8.17e-05	0.00248	CbGpPWpGaD
Lurasidone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.1e-05	0.00246	CbGpPWpGaD
Lurasidone—ADRA2A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	8.01e-05	0.00243	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.95e-05	0.00242	CbGpPWpGaD
Lurasidone—DRD2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.9e-05	0.0024	CbGpPWpGaD
Lurasidone—DRD2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.9e-05	0.0024	CbGpPWpGaD
Lurasidone—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.9e-05	0.0024	CbGpPWpGaD
Lurasidone—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7.84e-05	0.00238	CbGpPWpGaD
Lurasidone—HTR2A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.78e-05	0.00236	CbGpPWpGaD
Lurasidone—HTR2A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.78e-05	0.00236	CbGpPWpGaD
Lurasidone—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.77e-05	0.00236	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.72e-05	0.00235	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.7e-05	0.00234	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.6e-05	0.00231	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.53e-05	0.00229	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	7.53e-05	0.00229	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—AGPS—acquired immunodeficiency syndrome	7.52e-05	0.00228	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—IFNA1—acquired immunodeficiency syndrome	7.46e-05	0.00227	CbGpPWpGaD
Lurasidone—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	7.43e-05	0.00226	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.41e-05	0.00225	CbGpPWpGaD
Lurasidone—ADRA2C—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	7.38e-05	0.00224	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	7.33e-05	0.00223	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	7.3e-05	0.00222	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—TAT—acquired immunodeficiency syndrome	7.18e-05	0.00218	CbGpPWpGaD
Lurasidone—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7.11e-05	0.00216	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.08e-05	0.00215	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.08e-05	0.00215	CbGpPWpGaD
Lurasidone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.07e-05	0.00215	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	7.01e-05	0.00213	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	7.01e-05	0.00213	CbGpPWpGaD
Lurasidone—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7e-05	0.00213	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.98e-05	0.00212	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.91e-05	0.0021	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.87e-05	0.00209	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	6.87e-05	0.00208	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	6.87e-05	0.00208	CbGpPWpGaD
Lurasidone—HTR1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.85e-05	0.00208	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.74e-05	0.00205	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	6.63e-05	0.00201	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.63e-05	0.00201	CbGpPWpGaD
Lurasidone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.37e-05	0.00193	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.34e-05	0.00193	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.25e-05	0.0019	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	6.23e-05	0.00189	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	6.23e-05	0.00189	CbGpPWpGaD
Lurasidone—HTR1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.17e-05	0.00187	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—AGPS—acquired immunodeficiency syndrome	6.11e-05	0.00186	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—IFNA1—acquired immunodeficiency syndrome	6.06e-05	0.00184	CbGpPWpGaD
Lurasidone—DRD2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.01e-05	0.00183	CbGpPWpGaD
Lurasidone—ADRA2A—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	5.99e-05	0.00182	CbGpPWpGaD
Lurasidone—ADRA2C—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	5.98e-05	0.00182	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.97e-05	0.00181	CbGpPWpGaD
Lurasidone—HTR1A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	5.95e-05	0.00181	CbGpPWpGaD
Lurasidone—HTR2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.92e-05	0.0018	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—CSF2—acquired immunodeficiency syndrome	5.84e-05	0.00177	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.43e-05	0.00165	CbGpPWpGaD
Lurasidone—DRD2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.42e-05	0.00165	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.41e-05	0.00164	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.38e-05	0.00163	CbGpPWpGaD
Lurasidone—HTR2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.33e-05	0.00162	CbGpPWpGaD
Lurasidone—HTR7—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	5.29e-05	0.00161	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.26e-05	0.0016	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.24e-05	0.00159	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.22e-05	0.00159	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.2e-05	0.00158	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.2e-05	0.00158	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.14e-05	0.00156	CbGpPWpGaD
Lurasidone—HTR2A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	5.14e-05	0.00156	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.09e-05	0.00155	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.09e-05	0.00155	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.03e-05	0.00153	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.03e-05	0.00153	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.92e-05	0.0015	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.92e-05	0.0015	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.91e-05	0.00149	CbGpPWpGaD
Lurasidone—ADRA2A—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	4.86e-05	0.00148	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.85e-05	0.00147	CbGpPWpGaD
Lurasidone—HTR1A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	4.8e-05	0.00146	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.77e-05	0.00145	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.76e-05	0.00144	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.75e-05	0.00144	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.74e-05	0.00144	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—CSF2—acquired immunodeficiency syndrome	4.74e-05	0.00144	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.71e-05	0.00143	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.7e-05	0.00143	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.69e-05	0.00143	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.67e-05	0.00142	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.67e-05	0.00142	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.62e-05	0.0014	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.62e-05	0.0014	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.56e-05	0.00139	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.56e-05	0.00139	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.55e-05	0.00138	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.49e-05	0.00136	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.49e-05	0.00136	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.47e-05	0.00136	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.47e-05	0.00136	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.47e-05	0.00136	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.47e-05	0.00136	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.4e-05	0.00133	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.4e-05	0.00133	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.33e-05	0.00132	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.31e-05	0.00131	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.27e-05	0.0013	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.27e-05	0.0013	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.25e-05	0.00129	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.25e-05	0.00129	CbGpPWpGaD
Lurasidone—HTR2A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	4.15e-05	0.00126	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.13e-05	0.00125	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.08e-05	0.00124	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.08e-05	0.00124	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.06e-05	0.00123	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.06e-05	0.00123	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.06e-05	0.00123	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4e-05	0.00121	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4e-05	0.00121	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.99e-05	0.00121	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.99e-05	0.00121	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.92e-05	0.00119	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.87e-05	0.00118	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.86e-05	0.00117	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.81e-05	0.00116	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—ALB—acquired immunodeficiency syndrome	3.8e-05	0.00116	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.75e-05	0.00114	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.69e-05	0.00112	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.69e-05	0.00112	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.68e-05	0.00112	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.68e-05	0.00112	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.63e-05	0.0011	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.63e-05	0.0011	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.51e-05	0.00107	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.49e-05	0.00106	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.46e-05	0.00105	CbGpPWpGaD
Lurasidone—DRD2—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	3.44e-05	0.00105	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.4e-05	0.00103	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.4e-05	0.00103	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.37e-05	0.00102	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.35e-05	0.00102	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.35e-05	0.00102	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.34e-05	0.00102	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.29e-05	0.001	CbGpPWpGaD
Lurasidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.21e-05	0.000975	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.21e-05	0.000975	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.17e-05	0.000962	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.11e-05	0.000943	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—ALB—acquired immunodeficiency syndrome	3.09e-05	0.000938	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.09e-05	0.000937	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—IL2—acquired immunodeficiency syndrome	3.08e-05	0.000937	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.06e-05	0.00093	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.06e-05	0.00093	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	3.06e-05	0.00093	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.04e-05	0.000924	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.04e-05	0.000923	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.04e-05	0.000922	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.01e-05	0.000915	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3e-05	0.00091	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.99e-05	0.000908	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.9e-05	0.000882	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.82e-05	0.000856	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.81e-05	0.000853	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.8e-05	0.000851	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.78e-05	0.000844	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.77e-05	0.000842	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.76e-05	0.000839	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.76e-05	0.000838	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.74e-05	0.000832	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.74e-05	0.000831	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.73e-05	0.000829	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.73e-05	0.000829	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.72e-05	0.000826	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.72e-05	0.000826	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.64e-05	0.000802	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.64e-05	0.000802	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	2.6e-05	0.00079	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.55e-05	0.000774	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.52e-05	0.000767	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.52e-05	0.000766	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.51e-05	0.000762	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	2.51e-05	0.000761	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.49e-05	0.000756	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.47e-05	0.00075	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.4e-05	0.000728	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.4e-05	0.000728	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.36e-05	0.000716	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.36e-05	0.000716	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.28e-05	0.000693	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.15e-05	0.000651	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.15e-05	0.000651	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.08e-05	0.000631	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.05e-05	0.000621	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.01e-05	0.000612	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.01e-05	0.00061	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.98e-05	0.000601	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.95e-05	0.000592	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.87e-05	0.000568	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.83e-05	0.000556	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.82e-05	0.000554	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.81e-05	0.00055	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.8e-05	0.000545	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.79e-05	0.000545	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.77e-05	0.000538	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.77e-05	0.000537	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.77e-05	0.000537	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.74e-05	0.000529	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.64e-05	0.000499	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.63e-05	0.000496	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.62e-05	0.000491	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.61e-05	0.000488	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.61e-05	0.000488	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.58e-05	0.000481	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.58e-05	0.00048	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—ALB—acquired immunodeficiency syndrome	1.54e-05	0.000468	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.47e-05	0.000446	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.46e-05	0.000443	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.45e-05	0.000441	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.44e-05	0.000437	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	1.25e-05	0.00038	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.08e-05	0.000328	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.08e-05	0.000327	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.05e-05	0.000318	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.04e-05	0.000316	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.49e-06	0.000288	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.44e-06	0.000287	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.34e-06	0.000284	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.29e-06	0.000282	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.57e-06	0.00026	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.49e-06	0.000258	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.45e-06	0.000257	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.35e-06	0.000193	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.15e-06	0.000187	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.58e-06	0.000169	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.49e-06	0.000167	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	5.34e-06	0.000162	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.99e-06	0.000152	CbGpPWpGaD
